612 related articles for article (PubMed ID: 16019360)
1. Serum luteinizing hormone, follicle-stimulating hormone and oestradiol pattern in women undergoing pituitary suppression with different gonadotrophin-releasing hormone analogue protocols for assisted reproduction.
Manna C; Rahman A; Sbracia M; Pappalardo S; Mohamed EI; Linder R; Nardo LG
Gynecol Endocrinol; 2005 Apr; 20(4):188-94. PubMed ID: 16019360
[TBL] [Abstract][Full Text] [Related]
2. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
[TBL] [Abstract][Full Text] [Related]
3. [A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization].
Ye H; Huang G; Pei L
Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):222-5. PubMed ID: 11783366
[TBL] [Abstract][Full Text] [Related]
4. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
[TBL] [Abstract][Full Text] [Related]
5. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.
De Placido G; Alviggi C; Perino A; Strina I; Lisi F; Fasolino A; De Palo R; Ranieri A; Colacurci N; Mollo A;
Hum Reprod; 2005 Feb; 20(2):390-6. PubMed ID: 15576390
[TBL] [Abstract][Full Text] [Related]
7. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
8. IVF/ICSI outcome and serum LH concentration on day 1 of ovarian stimulation with recombinant FSH under pituitary suppression.
Bjercke S; Fedorcsak P; Abyholm T; Storeng R; Ertzeid G; Oldereid N; Omland A; Tanbo T
Hum Reprod; 2005 Sep; 20(9):2441-7. PubMed ID: 15919773
[TBL] [Abstract][Full Text] [Related]
9. [Effect of concentration of circulating luteinizing hormone in late-follicle phase on the outcome of in vitro fertilization for normogonadotrophic women].
Sun H; Hu Y; Wang B; Chen Q; Zhang N; Chen H; Wang J; Xu Z
Zhonghua Nan Ke Xue; 2004 Dec; 10(12):912-5. PubMed ID: 15638021
[TBL] [Abstract][Full Text] [Related]
10. Long GnRH-agonist protocol in an IVF program. Is it appropriate for women with normal FSH levels and high FSH/LH ratios?
Yang JH; Wu MY; Chao KH; Chen SU; Ho HN; Yang YS
J Reprod Med; 1997 Oct; 42(10):663-8. PubMed ID: 9350023
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
12. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
[TBL] [Abstract][Full Text] [Related]
13. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
Itskovitz-Eldor J; Kol S; Mannaerts B
Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
[TBL] [Abstract][Full Text] [Related]
14. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction.
Westergaard LG; Laursen SB; Andersen CY
Hum Reprod; 2000 May; 15(5):1003-8. PubMed ID: 10783342
[TBL] [Abstract][Full Text] [Related]
16. [Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats].
Peng P; Yang DZ; Zheng CY; Mo YQ; He YM; Zhang QX
Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):546-50. PubMed ID: 17983495
[TBL] [Abstract][Full Text] [Related]
17. Does day-3 LH/FSH ratio influence in vitro fertilization outcome in PCOS patients undergoing controlled ovarian hyperstimulation with different GnRH-analogue?
Orvieto R; Meltcer S; Liberty G; Rabinson J; Anteby EY; Nahum R
Gynecol Endocrinol; 2012 Jun; 28(6):422-4. PubMed ID: 22578028
[TBL] [Abstract][Full Text] [Related]
18. Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients.
Hosseini MA; Aleyasin A; Saeedi H; Mahdavi A
J Obstet Gynaecol Res; 2010 Jun; 36(3):605-10. PubMed ID: 20598044
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
[TBL] [Abstract][Full Text] [Related]
20. Comparison between "short" and "long" protocols in an ICSI programme.
Loutradis D; Stefanidis K; Drakakis P; El Sheikh A; Milingos S; Antsaklis A; Michalas S
Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):69-72. PubMed ID: 15866089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
